To determine the replicability of our observed age-associated differences in immunotherapy responses in patients with aNSCLC, we established preclinical models using two immunotherapy (anti-PD-1/PD-L1) sensitive mouse colon cancer cell lines MC38 and CT26. This evidence concerns the gene CD274 and colonic neoplasm.